

BÖLÜM 18

OLİGOMETASTATİK MEME KANSERİNDE CERRAHİ TEDAVİ

Mustafa Ümit UĞURLU¹

GİRİŞ

Meme kanseri kadınlarda en sık kanser olup, kansere bağlı ölümlerde dünyada ikinci sırada yer almaktadır (1). Metastatik meme kanseri, olguların % 5-6'sını oluşturmakta, erken-evre meme kanserlerinin %20-30'u takiplerde uzak metastaz şeklinde nüks etmektedir (2). Metastatik meme kanserlerinin klinik davranışı tümör biyolojisine bağlı olarak değişmekle birlikte (örn. Hormon reseptör pozitif meme kanseri-predominant kemik metastazı) tümör yükü, Evre 4 tümörlerin prognozunun tayininde önem taşımaktadır. Metastatik meme kanserli olguların bir bölümü ≤ 5 tümör depoziti ile, sınırlı organ tutulumu ile prezente olup "oligometastatik meme kanseri" (OMMK) olarak tanımlanmaktadır. OMMK'nın insidansı tam olarak bilinmemekle birlikte Evre 4 olguların %20'sinin oligometastatik hastalık olarak görüldüğü bildirilmiştir (3).

Meme kanserinde "Oligometastaz" konsepti, 1995'te Hellman ve ark. tarafından tanımlandığından bu yana, OMMK'nın polimetastatik hastalıktan farklı seyir izlediği, daha iyi prognoz ve sağkalım sonuçlarına sahip olduğu, hatta multimodal tedavilerle olguların %2-3'ünde kür sağlanabildiği gösterilmiştir (4-6).

Meme kanserinde oligometastatik davranışın genellikle düşük maliğn potansiyele sahip pluripotent hücre serilerinden kaynaklandığı öngörülmekte olup oligometastatik evrede tespit edilen olguların karsinogeneizde "ara" evre oldukları, bu sebeple çoğu durumda indolan, non-progresif seyir izledikleri düşünülmektedir

¹ Doç. Dr., Marmara Üniversitesi Tıp Fakültesi Genel Cerrahi AD. umitugurlu@gmail.com

KAYNAKLAR

1. Niederhuber JEAMD. Abeloff's clinical oncology 2020.
2. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. *Oncologist*. 2005
3. Jain SK, Dorn PL, Chmura SJ, Weichselbaum RR, Hasan Y. Incidence and implications of oligometastatic breast cancer. *American Society of Clinical Oncology*; 2012.
4. Hellman S Fau - Weichselbaum RR, Weichselbaum RR. Oligometastases. *J Clin Oncol*. 1995;13(1):8-10.
5. Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. *Oncotarget*. 2015;6(11):8491-524.
6. Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). *Ann Oncol*. 2017;28(1):16-33.
7. Gupta GP, Massagué J. Cancer metastasis: building a framework. *Cell*. 2006;127(4):679-95.
8. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. *Cancer Discov*. 2015;5(11):1164-77.
9. Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, et al. MicroRNA expression characterizes oligometastasis(es). *PLoS One*. 2011;6(12):e28650.
10. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. *Jpn J Clin Oncol*. 2010;40(2):107-11.
11. Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Contemporary surgical treatment of advanced-stage melanoma. *Arch Surg*. 2004;139(9):961-6; discussion 6-7.
12. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. *N Engl J Med*. 2001;345(23):1655-9.
13. Rosen SA, Buell JF, Yoshida A, Kazsuba S, Hurst R, Michelassi F, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? *Arch Surg*. 2000;135(5):530-4; discussion 4-5.
14. Westphal T, Gampenrieder SP, Rinnerthaler G, Greil R. Cure in metastatic breast cancer. *memo - Magazine of European Medical Oncology*. 2018;11(3):172-9.
15. Pagani O, Senkus E Fau - Wood W, Wood W Fau - Colleoni M, Colleoni M Fau - Cufer T, Cufer T Fau - Kyriakides S, Kyriakides S Fau - Costa A, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? *J Natl Canc Inst*. 2010;102(7):456-63.
16. Rashid OM, Nagahashi M Fau - Ramachandran S, Ramachandran S Fau - Graham L, Graham L Fau - Yamada A, Yamada A Fau - Spiegel S, Spiegel S Fau - Bear HD, et al. Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. *Surgery*. 2013;153(6):771-8.
17. Blanchard DK, Shetty Pb Fau - Hilsenbeck SG, Hilsenbeck Sg Fau - Elledge RM, Elledge RM. Association of surgery with improved survival in stage IV breast cancer patients. *Ann Surg*. 2008;247(5): 732-8.
18. Vohra NA, Brinkley J, Kachare S, Muzaffar MA-O. Primary tumor resection in metastatic breast cancer: A propensity-matched analysis, 1988-2011 SEER data base. *Breast J*. 2008;24(4):549-54.
19. Barinoff J, Schmidt M, Schneeweiss A, Schoenegg W, Thill M, Keitel S, et al. Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgery. *Eur J Cancer* 2017;83.
20. Khan SA-O, Zhao F, Goldstein LA-O,, et al. Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108). *JCO* 2022;20.
21. Fitzal F, Bjelic-Radisic V, Knauer M, et al. Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYITIVE Trial. *Ann Surg* 2019;269(6).
22. Bjelic-Radisic VA-O, Fitzal F, et al. Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized

- multicenter ABCSG-28 Posytive Trial. *BMC Cancer* 2020; 6(20).
23. Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. *Lancet Oncol* 2015;16(13).
 24. Soran A, Ozmen V, Ozbas S, et al. Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. *Ann Surg Oncol* 2018; 25(11).
 25. Soran AA-O, Soyder A, Ozbas S, et al. The role of loco-regional treatment in long-term quality of life in de novo stage IV breast cancer patients: protocol MF07-01Q. *Support Care Cancer* 2021;29(7).
 26. Soran A, Ozmen V, Ozbas S, et al. Primary Surgery with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-year Follow-up; Protocol MF07-01 Randomized Clinical Trial. *J Am Coll Surg* 2021;233(6).
 27. Chua TC, Saxena A Fau - Liauw W, et al. Hepatic resection for metastatic breast cancer: a systematic review. *Eur J Cancer* 2011; 47(15).
 28. Yoo TG, Cranshaw I, Broom R, Pandanaboyana S, Bartlett A. Systematic review of early and long-term outcome of liver resection for metastatic breast cancer: Is there a survival benefit? *Breast* 2017; 32.
 29. Sadot E, Lee SY, Sofocleous CT, et al. Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients. *Ann Surg* 2009;264(1).
 30. Raab R, Nussbaum Kt Fau et al. Liver metastases of breast cancer: results of liver resection. *Anticancer Res* 1998.
 31. Yoshimoto M, Tada T Fau - Saito M, et al. Surgical treatment of hepatic metastases from breast cancer. *Breast Can Res Treat* 200;59(2).
 32. Pocard M, Pouillart P Fau et al. [Hepatic resection for breast cancer metastases: results and prognosis (65 cases)]. *Ann Chir* 2001;126(5).
 33. Elias D, Maisonneuve F Fau, et al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. *Am J Surg* 2003;185(2).
 34. Vlastos G, Smith DI Fau et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. *Ann Surg Oncol* 2004;11(9).
 35. Sakamoto Y, Yamamoto J Fau - Yoshimoto M, et al. Hepatic resection for metastatic breast cancer: prognostic analysis of 34 patients. *World J Surg* 2005;29(4).
 36. Adam R, Aloia T Fau - Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? *Ann Surg* 2006;244(6).
 37. Zegarac M, Nikolic S Fau, et al. Prognostic factors for longer disease free survival and overall survival after surgical resection of isolated liver metastasis from breast cancer. *J BUON* 2013.
 38. Weinrich M, Weiß C, Schuld J, Rau BM. Liver resections of isolated liver metastasis in breast cancer: results and possible prognostic factors. *HPB Surg* 2014.
 39. Ye T Fau - Yang B, Yang B Fau - Tong H et al. Long-Term Outcomes Of Surgical Resection for Liver Metastasis from Breast Cancer. *Hepatogastroenterology* 2015; 62(139).
 40. Margonis GA, Buettner S, Sasaki K, Kim Y, Ratti F, Russolillo N, et al. The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis. *HPB* 2016; 18(8).
 41. Song Z, Ye T, Ma L, Xiang J, Chen H. Surgical Outcomes of Isolated Malignant Pulmonary Nodules in Patients with a History of Breast Cancer. *Ann Surg Oncol* 2017;24(12).
 42. Fan J, Chen D, Du H, Shen C, Che G. Prognostic factors for resection of isolated pulmonary metastases in breast cancer patients: a systematic review and meta-analysis. *J Thor Dis* 2015;7(8).
 43. Noble J, Sirohi B Fau et al. Sternal/para-sternal resection for parasternal local recurrence in breast cancer. *Breast* 2010;19(5).
 44. Li W, Wang H Fau et al. Ovarian metastases resection from extragenital primary sites: outcome and prognostic factor analysis of 147 patients. *BMC Cancer* 2012;3(12).
 45. McLemore EC, Pockaj Ba Fau - Reynolds C., et al. Breast cancer: presentation and intervention in women with gastrointestinal metastasis and carcinomatosis. *Ann Surg Oncol* 2005;12(11).